Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Mar
11
Today In Oncology
Stanford Names Leader for Drug Development and Precision Oncology
Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer
Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks
FDA Releases Updated Guidance on Biosimilar Development
SABCS 2025: High-Level Review of Select Data
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo